Bio-Rad Laboratories, Inc.
BIO
$238.68
-$2.34-0.97%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -12.30% | 2.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.30% | 2.73% | |||
| Cost of Revenue | -15.59% | 10.80% | |||
| Gross Profit | -9.16% | -3.93% | |||
| SG&A Expenses | -5.31% | 2.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.30% | 4.17% | |||
| Operating Income | -1.78% | -10.28% | |||
| Income Before Tax | 109.18% | -205.49% | |||
| Income Tax Expenses | 110.05% | -192.64% | |||
| Earnings from Continuing Operations | 108.94% | -209.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 108.94% | -209.59% | |||
| EBIT | -1.78% | -10.28% | |||
| EBITDA | -2.19% | -6.12% | |||
| EPS Basic | 108.96% | -209.40% | |||
| Normalized Basic EPS | 34.95% | -6.37% | |||
| EPS Diluted | 108.96% | -209.54% | |||
| Normalized Diluted EPS | 34.88% | -6.25% | |||
| Average Basic Shares Outstanding | -0.20% | 0.17% | |||
| Average Diluted Shares Outstanding | -0.15% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||